- Home
- GRF vs ALGS Comparison
GRF vs ALGS Comparison
Compare GRF & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GRF | ALGS |
|---|---|---|
| Founded | 1989 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.9M | 49.7M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | GRF | ALGS |
|---|---|---|
| Price | $10.59 | $6.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $46.67 |
| AVG Volume (30 Days) | 1.5K | ★ 34.9K |
| Earning Date | 01-01-0001 | 06-15-2026 |
| Dividend Yield | ★ 3.70% | N/A |
| EPS Growth | N/A | ★ 88.30 |
| EPS | ★ 1.16 | N/A |
| Revenue | N/A | ★ $2,186,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.13 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.86 | $3.76 |
| 52 Week High | $11.85 | $13.69 |
Technical Indicators
Market Signals| Indicator | GRF | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 46.40 | 45.41 |
| Support Level | $10.43 | $6.92 |
| Resistance Level | $11.01 | $8.84 |
| Average True Range (ATR) | 0.17 | 0.56 |
| MACD | -0.03 | 0.06 |
| Stochastic Oscillator | 23.96 | 58.27 |
Price Performance
Historical ComparisonAbout GRF Eagle Capital Growth Fund Inc.
Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock by giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.